This cross-sectional study explored the association between medication non-adherence and its factors in patients with non-communicable diseases (NCDs) using an online structured questionnaire emailed to 30,000 people (aged over 20 years who lived in Japan at the time of the survey). The questions concerned respondents’ characteristics, medication non-adherence, health beliefs, lifestyles, and trouble taking medication. Factors related to non-adherence were analyzed among patients with lifestyle-related NCDs categorized into two age groups: 20–59, and >60 years. Unintentional (p < 0.001) and intentional (p < 0.001) non-adherence were more common among patients aged 20–59 than in older adults. NCD patients aged 20–59 experienced significantly more trouble taking medication than older adults. Multiple regression analysis showed that for patients aged 20–59 with NCDs, unintentional non-adherence was significantly and positively associated with current smoking habits (β = 0.280, p < 0.001), while intentional non-adherence was significantly and positively associated with alcohol consumption (β = 0.147, p = 0.020) and current smoking habits (β = 0.172, p = 0.007). In patients aged 20–59, unhealthy eating habits (β = −0.136, p = 0.034) and lack of exercise (β = −0.151, p = 0.020) were negatively associated with intentional non-adherence. In conclusion, factors affecting medication non-adherence in patients with lifestyle-related diseases are related to health awareness, lifestyle, and medication barriers.

Purpose: Antihistamine over-the-counter (OTC) drugs for allergic rhinitis are widely used and cause central nervous system side effects. Most available data on anti-allergic drugs are on controlled usage. It is necessary to investigate the occurrence of side effects in the context of self-medication to avoid inappropriate use. We aimed to clarify the association between the usage of OTC anti-allergic drugs and central nervous system side effects. Patients and Methods: An online, anonymous, cross-sectional study was conducted using a structured questionnaire. People who had used OTC anti-allergic drugs in the year prior to the study were recruited. To assess the association between inappropriate drug use and the occurrence of side effects, a binary logistics regression analysis was performed according to three dosage forms (oral only, nasal only, and oral and nasal combined use). Results: Somnolence was experienced by 59.1% of the participants using the OTC drug for allergic rhinitis. Using logistic regression analysis, “drug use exceeding the upper limit” was seen to be associated with side effects in only oral (Somnolence: OR = 1.41, 95% CI = 1.17– 1.70; Dull head: OR=1.41, 95% CI = 1.16– 1.70; Loss of concentration: OR = 1.25, 95% CI = 1.04– 1.49) and oral and nasal combined use groups (Somnolence: OR = 1.33, 95% CI = 1.04– 1.71; Dull head: OR = 1.47, 95% CI = 1.15– 1.89; Loss of concentration: OR = 1.51, 95% CI = 1.19– 1.91). Furthermore, “expired drug use” was associated with side effects in the nasal spray-only group (Somnolence: OR = 1.31, 95% CI = 1.07– 1.60; Dull head: OR =1.25, 95% CI = 1.02– 1.53; Loss of concentration: OR = 1.24, 95% CI = 1.00– 1.54). Conclusion: Inappropriate use was common among users of OTC allergic rhinitis drugs. Differences in side effects depending on the dosage form used were observed.

Background: Adolescent athletes’ values ​regarding health behaviors, including their attitudes toward doping, are largely derived from those of their parents. Therefore, clarifying the factors that affect parents’ intentions regarding their children’s medicine intake and nutrition can help elucidate the process of forming values ​​of healthy behaviors in young athletes.Methods: Between March 8 and March 9, 2021, an online questionnaire survey was conducted via an Internet research company; data from 2,000 residents in Japan were collected. Participants were male and female residents aged 30–59 years with children in elementary or high school and belonging to sports clubs. The survey items included respondent’s and child’s basic information, respondent’s health literacy, and level of sports in which the respondent and child were (or are) engaged. Respondents were also asked if they would like their children to receive prescription drugs, over-the-counter drugs, herbal medicines, vaccines, supplements, or energy drinks. Logistic regression analysis was performed to analyze the relationship between respondents’ basic information and health literacy and their intention to receive prescription and over-the-counter drugs, herbal medicines, vaccines, supplements, and energy drinks.Results: Higher parental health literacy was associated with higher children’s willingness to receive prescription drugs (odds ratio [OR] = 1.025, 95% confidence interval [CI]: 1.016–1.035), over-the-counter drugs (OR = 1.012, 95% CI: 1.003–1.021), prescription herbal medicines (OR = 1.021, 95% CI: 1.021–1.030), over-the-counter herbal medicines (OR = 1.012, 95% CI: 1.003–1.021), and vaccines (OR = 1.025, 95% CI: 1.016–1.035). Conversely, the children’s intention to receive energy drinks (OR = 0.990, 95% CI: 0.980–1.000) decreased significantly. As the child’s athletic level increased, parents’ willingness for their children to receive oral prescription medicines decreased (OR = 0.886, 95% CI: 0.791–0.992) and that to receive supplements (OR = 1.492, 95% CI: 1.330–1.673) and energy drinks significantly increased (OR = 1.480, 95% CI: 1.307–1.676).Conclusion: Health literacy of adolescent athletes’ parents is associated with their children’s willingness to receive medicines. Healthcare providers should counsel parents of adolescent athletes to allow their children to receive necessary drug treatments and prevent doping violations caused by supplement intake.

In this study, we conducted a survey and interviews of young athletes to clarify the actual conditions of medication use and nutritional management (supplement use, etc.) with the aim of enhancing their health support. In addition, a second questionnaire was conducted for pharmacists working at medical institutions to clarify the actual situation of anti-doping (AD) activities by pharmacists, and examined the issues they face to support the health of athletes in the future. The results of the athletes' surveys revealed that the roles of pharmacists in AD activities was not recognized by athletes. In particular, the dissemination of AD education by pharmacists is considered to be critical. In future AD education, it will be necessary not only to provide knowledge of prohibited drugs, but also to provide self-medication support tailored to the individual needs of athletes, such as knowledge of nutrition and health. The results of the pharmacist survey revealed that athletes are treated by pharmacists on a daily basis, but for pharmacists, there are difficulties regarding how to provide information on AD, and it is necessary to enhance AD education at schools of pharmacy as well as in lifelong education seminars. Considering the pharmacists' AD activities as part of health support for athletes, it is considered more effective to collaborate with other health professionals such as sports doctors or nutritionists because it requires a wide range of knowledge such as nutrition.

Molnupiravir and ensitrelvir are widely used for outpatient coronavirus disease 2019 treatment; however, real-world safety comparisons remain limited. This retrospective cohort study evaluated acute clinical event risks over a 29-day follow-up using community pharmacy records from Japanese patients newly prescribed either drug between January and September 2023. Hazard ratios (HRs) were estimated using multivariable Cox proportional hazard models. The analysis included 2051 patients prescribed molnupiravir and 563 prescribed ensitrelvir. Patients prescribed molnupiravir were older and had a higher prevalence of comorbidities than those prescribed ensitrelvir. However, after multivariable adjustment, no significant differences in the risk of major symptoms, such as diarrhea or vertigo, or overall add-on drug prescription were observed between the patient groups. An exception was anti-inflammatory drugs, with a significantly higher risk in the molnupiravir group (adjusted HR: 3.44, 95% confidence interval: 1.07–11.06). These results indicate that while short-term acute clinical event profiles were broadly comparable between molnupiravir and ensitrelvir in routine practice, the differences in add-on prescriptions, combined with the observational study design and limited statistical power in sub-analyses, highlight persistent clinical uncertainty. Our findings provide real-world evidence complementary to that from randomized controlled trials and emphasize the need for larger future studies.